Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment
Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.
Bristol Myers Squibb just got permission from the government to sell a new medicine for a serious blood disease called multiple myeloma. This is good news because it shows the company's research works, and doctors can now help more patients with this treatment.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.